@Article{ecn.2016.0384,
AUTHOR = {Anwar D. Maraqa},
TITLE = {Effect of atorvastatin on interleukins and prostaglandin E2 in the kidney of type 1 diabetic rats},
JOURNAL = {European Cytokine Network},
VOLUME = {27},
YEAR = {2016},
NUMBER = {4},
PAGES = {97--101},
URL = {http://www.techscience.com/ECN/v27n4/65530},
ISSN = {1952-4005},
ABSTRACT = {The aim of the study was to evaluate a possible effect of atorvastatin on renal interleukins
(ILs) and prostaglandin E2 (PGE2) in type 1 diabetic rats. Methods: Thirty-two male rats from a local Wister-derived
strain were included in this prospective study and were classified into four groups. Each group consisted of
eight animals: Group 1, non-diabetic negative controls; Group 2, diabetic positive controls; Group 3, non-diabetic
rats receiving atorvastatin for 4 weeks; and Group 4, diabetic rats receiving atorvastatin for 4 weeks. At the end
of the designated period, the animals were sacrificed by cervical dislocation, and the kidneys were excised and
homogenized to determine the level of IL-1β, IL-6, IL-10, and PGE2. The study duration was from June 2015 to
May 2016 at Al-Ahlyya Amman University, Amman, Jordan. Results: In the kidneys of rats with streptozotocin-induced
diabets, the levels of cytokines IL-1β, IL-6, IL-10, and PGE2 were significantly elevated above those of the
control group. This clearly showed a detrimental effect of diabetes on the kidney. Treatment of diabetic rats with
atorvastatin caused a decrease in all evaluated cytokines to levels near control values. Conclusion: Our data suggest
that atorvastatin has the potential to protect or attenuate diabetes-induced renal injury. However, the possible
protective effect of atorvastatin should be supported by clinical evidence.},
DOI = {10.1684/ecn.2016.0384}
}